| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5640 | 2021 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1765 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1404 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 767 | 2021 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 284 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ... The lancet HIV 8 (8), e474-e485, 2021 | 235 | 2021 |
| Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open … SP Bach, A Gilbert, K Brock, S Korsgen, I Geh, J Hill, T Gill, P Hainsworth, ... The lancet Gastroenterology & hepatology 6 (2), 92-105, 2021 | 152 | 2021 |
| Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection AJ Mentzer, D O’connor, S Bibi, I Chelysheva, EA Clutterbuck, T Demissie, ... Nature medicine 29 (1), 147-157, 2023 | 64 | 2023 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil SAC Clemens, PM Folegatti, KRW Emary, LY Weckx, J Ratcliff, S Bibi, ... Nature Communications 12 (1), 5861, 2021 | 51 | 2021 |
| COVID-19 Genomics UK consortium; AMPHEUS Project KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19 (AZD1222 …, 2021 | 51 | 2021 |
| Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV A Ogbe, M Pace, M Bittaye, T Tipoe, S Adele, J Alagaratnam, PK Aley, ... JCI insight 7 (7), 2022 | 37 | 2022 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial G Li, F Cappuccini, NG Marchevsky, PK Aley, R Aley, R Anslow, S Bibi, ... The Lancet 399 (10342), 2212-2225, 2022 | 35 | 2022 |
| Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer: randomized clinical trial British Journal of Surgery 109 (11), 1073-1080, 2022 | 34 | 2022 |
| Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study W Atkin, AJ Cross, I Kralj-Hans, E MacRae, C Piggott, S Pearson, ... Health Technology Assessment 23 (1), 1-84, 2019 | 30 | 2019 |
| An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females NG Marchevsky, G Li, P Aley, SAC Clemens, JR Barrett, ... EBioMedicine 81, 2022 | 12 | 2022 |
| Safety and immunogenicity of the ChAdox1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection J Frater, K Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ... | 8 | 2021 |
| Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV-responses to SARS-CoV-2, variants of concern and circulating coronaviruses A Ogbe, M Pace, M Bittaye, T Tipoe, S Adele, J Alagaratnam, PK Aley, ... medRxiv, 2021.09. 28.21264207, 2021 | 4 | 2021 |
| Status of primary and secondary mental healthcare of people with severe mental illness: an epidemiological study from the UK PARTNERS2 programme S Reilly, C McCabe, N Marchevsky, M Green, L Davies, N Ives, H Plappert, ... BJPsych Open 7 (2), e53, 2021 | 4 | 2021 |
| A randomized trial assessing the immunogenicity and reactogenicity of two hexavalent infant vaccines concomitantly administered with group B meningococcal vaccine M Rajan, N Marchevsky, G Sinclair, K O’Brien, K Jefferies, N Owino, ... The Pediatric Infectious Disease Journal 42 (1), 66-73, 2023 | 2 | 2023 |
| Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single … SA Costa Clemens, N Marchevsky, S Kelly, S Felle, A Eldawi, ... Human Vaccines & Immunotherapeutics 19 (2), 2233400, 2023 | 1 | 2023 |
